» Articles » PMID: 1544235

IL-2 Infusion Abrogates Humoral Immune Responses in Humans

Overview
Date 1992 Mar 1
PMID 1544235
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Although IL-2 infusion enhances cell-mediated cytotoxicity in patients with neoplastic disease, administration is paradoxically associated with a modest fall in total serum IgG and an increased risk of infection. We now show that the adverse effects of IL-2 infusion on the humoral immune system are substantial. Although IL-2 induces the B cell growth and differentiating factors IL-4 and IL-6, infusion abrogates primary antibody responses entirely and reduces secondary antibody responses 50-fold following antigen challenge. There is no evidence of the generation of cells with suppressive activity on B cells but IL-2 increases the ratio of circulating virgin:memory cells. These results may help to explain the increased rate of bacterial infection in patients receiving IL-2. As IL-2 plays a central role in the generation of an immune response, the finding that it is also sufficiently immunosuppressive to inhibit primary- and secondary-type antibody responses suggests that exploration of the underlying mechanisms may provide insights into immune system homeostasis and may offer new approaches to therapeutic immunosuppression.

Citing Articles

Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Kennedy-Nasser A, Ku S, Castillo-Caro P, Hazrat Y, Wu M, Liu H Clin Cancer Res. 2014; 20(8):2215-25.

PMID: 24573552 PMC: 3989436. DOI: 10.1158/1078-0432.CCR-13-3205.


Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.

Soubrane C, Mouawad R, Ichen M, Suissa J, Borel C, Vuillemin E Clin Exp Immunol. 1994; 95(2):232-6.

PMID: 8306497 PMC: 1534932. DOI: 10.1111/j.1365-2249.1994.tb06516.x.


Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Whittington R, Faulds D Drugs. 1993; 46(3):446-514.

PMID: 7693434 DOI: 10.2165/00003495-199346030-00009.


Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.

Vlasveld L, Hekman A, Vyth-Dreese F, Melief C, Sein J, Voordouw A Cancer Immunol Immunother. 1995; 40(1):37-47.

PMID: 7530170 PMC: 11037856. DOI: 10.1007/BF01517234.

References
1.
Romagnani S, Giudizi M, Biagiotti R, Almerigogna F, Mingari C, Maggi E . B cell growth factor activity of interferon-gamma. Recombinant human interferon-gamma promotes proliferation of anti-mu-activated human B lymphocytes. J Immunol. 1986; 136(10):3513-6. View

2.
Wimperis J, Brenner M, Prentice H, Reittie J, Karayiannis P, Griffiths P . Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet. 1986; 1(8477):339-43. DOI: 10.1016/s0140-6736(86)92315-9. View

3.
Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S . A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316(15):889-97. DOI: 10.1056/NEJM198704093161501. View

4.
Aarden L, de Groot E, Schaap O, Lansdorp P . Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987; 17(10):1411-6. DOI: 10.1002/eji.1830171004. View

5.
Waldmann T, Goldman C, Robb R, Depper J, Leonard W, Sharrow S . Expression of interleukin 2 receptors on activated human B cells. J Exp Med. 1984; 160(5):1450-66. PMC: 2187491. DOI: 10.1084/jem.160.5.1450. View